| Literature DB >> 35955439 |
Qun Liu1, Yan Huang1, Mengyun Duan2, Qun Yang2, Boxu Ren1, Fengru Tang3.
Abstract
Radiation-induced brain injury (RIBI) after radiotherapy has become an increasingly important factor affecting the prognosis of patients with head and neck tumor. With the delivery of high doses of radiation to brain tissue, microglia rapidly transit to a pro-inflammatory phenotype, upregulate phagocytic machinery, and reduce the release of neurotrophic factors. Persistently activated microglia mediate the progression of chronic neuroinflammation, which may inhibit brain neurogenesis leading to the occurrence of neurocognitive disorders at the advanced stage of RIBI. Fully understanding the microglial pathophysiology and cellular and molecular mechanisms after irradiation may facilitate the development of novel therapy by targeting microglia to prevent RIBI and subsequent neurological and neuropsychiatric disorders.Entities:
Keywords: brain injury; cognitive effects; ionizing radiation; microglia; therapy
Mesh:
Year: 2022 PMID: 35955439 PMCID: PMC9368164 DOI: 10.3390/ijms23158286
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Overview of the role of microglia in healthy brain and radiation-induced brain injury (RIBI). (A) Physiological functions of microglia in healthy brain. (B) The interaction of activated microglia with central nervous system (CNS) cell populations mediates the development of RIBI. Ionizing radiation (IR) directly induces microglial activation, while irradiated neurons and endothelial cells (ECs) release “danger” signals (high mobility group box 1, adenosine triphosphate, uridine diphosphate, and so on) to exacerbate microglial activation. By participating in complement cascade and secreting pro-inflammatory mediators such as TNF-α, interleukin-1 (IL-1), and prostaglandin E2 (PGE2), activated microglia can trigger the astrocytes activation, prevent neurogenesis and neural progenitor cell (NPC) differentiation, and stimulate the expression of intercellular adhesion molecule 1 (ICAM-1) in endothelial cells. ICAM-1 accumulation and blood–brain barrier (BBB) damage induced by IR cause the increased infiltration of peripheral immune cells, and this is exacerbated by monocyte chemoattractant protein-1 (MCP-1/CCL2) secreted by microglia. Subsequently, matrix metalloproteinases (MMPs) secreted by microglia and infiltrating cells further aggravate BBB damage.
Figure 2Schematic overview of receptors and exogenous molecules that modulate microglia phenotypes and functions in RIBI. Colony stimulating factor 1 receptor (CSF1R) blockade causes microglial death. Inhibition of P2X7 receptor (P2X7R) and KV1.3 channel or activation of (C-X3-C motif chemokine receptor 1) CX3CR1 and peroxisome proliferator-activated receptor (PPAR) prevent inflammatory gene expression in microglia. Activation of P2Y6 receptor (P2Y6R) and C3 receptor (CR3) mediate the phagocytosis of dying cells and synaptic components by microglia, respectively. Moreover, the introduction of exogenous molecules such as microRNA (miRNA), long non-coding RNAs (LncRNA), and extracellular vesicles (EVs) also enhance the therapeutic efficacy of RIBI. ATP, adenosine triphosphate; P, phosphorylation; NF-κB, nuclear factor κB; PI3K, phosphoinositide 3 kinases; AKT, protein kinase B; FKN, fractalkine; Shk-170, Stichodactyla helianthus-170; Pre-miRNA, precursor-miRNAs; siRNA, short interfering RNA; AP-1, activator protein 1; STAT, signal transducer and activator of transcription; Sirt1, sirtuin 1; ADMSC-Exos, exosomes derived from adipose mesenchymal stem cells.
Radioprotective effect of targeting different molecules in microglia in radiation-induced brain injury models.
| Targets | Animal/Cell Model | Source Dose and Dose Rate | Irradiated Site | Time Point after Radiation | Intervention Effect in Irradiation Models | Reference |
|---|---|---|---|---|---|---|
| CSFR1 | C57BL/6J mouse | X-ray with 9 cGy | whole brain | 3 days, 2 weeks, 6 weeks | CSFR1 inhibition reduces the increase in mRNA of inflammation markers (TLR9, SYK, CCL6, CD14, CLECL5a, TSLP, CCL5) and the number of activated microglia in hippocampus and ameliorates cognitive dysfunction. | [ |
| 4He particles with 30 cGy | 4–6 weeks | CSFR1 inhibition ameliorates cognitive dysfunction, reduces activated microglia population, and attenuates the increase in PSD-95 puncta but does not affect morphologic and electrophysiologic features of neurons. | [ | |||
| 4He particles with | 18–21 days and 90–100 days | CSFR1 inhibition improves long-term cognitive impairment and inflammatory response, decreases C5aR and LAMP-1, and increases synapsin-1. | [ | |||
| γ ray with three fractions of 3.3 Gy | 1, 3 months | CSFR1 blockade reduces the numbers of activated microglia, suppresses monocyte accumulation in brain, and ameliorates cognitive dysfunction. | [ | |||
| C1q | C57BL/6 mouse | γ-ray with 9 Gy | whole brain | 2, 24, 48 h; 1, 2, 3, 4 weeks | Deletion of C1q in microglia protects synaptic loss and reduces activation of microglia and astrocytes, as well as protein levels of TNF-a, IL-1ß, IL-6, IL-1α, CCL2, IL-18, and TLR4. | [ |
| C3 | C57BL/6 mouse | X-ray with 8 Gy | whole brain | 6 h; 7 days; 2, 3, 4 weeks | C3 knockout improves task performance and increases activated microglia and proliferating cells in the granule cell layer. | [ |
| C3R | C57BL/6J mouse | γ-ray with 10 Gy | whole brain | 30 days | CR3 blockade ameliorates behavior deficits in novel object recognition and the Lashley III maze, prevents dendritic spine loss, and increases CD11-positive microglia in hippocampus. | [ |
| 30, 45 days | CR3 knockout prevents dendritic spine loss and increases activated microglia in hippocampus. | [ | ||||
| P2Y6 | Balb/c mouse | β-ray with 30 Gy | whole brain | 1, 14, 30 days | P2Y6 receptor antagonism suppresses phagocytosis of irradiated microglia and increases the number of apoptotic neurons. | [ |
| Primary microglia | β-ray with 8 Gy | 4, 12, 48 h | P2Y6 receptor antagonism suppresses phagocytosis of irradiated microglia and has no effect on the production of inflammatory mediators (TNF-α, IL-1β, IL-6, iNOS). | [ | ||
| P2X7 | Balb/c mouse | β-ray with 30 Gy | whole brain | 3, 7, 14 days; 8 weeks | P2X7R blockade reduces the activated microglia population and neuron loss in the cortex. | [ |
| Primary microglia | β-ray with 10 Gy | 24, 48 h | P2X7R blockade reduces the activated microglia population and mRNA expression levels of IL-6, TNF-α, and COX-2. | [ | ||
| CX3CR1 | C57BL/6J mouse | γ-ray with 10 Gy | whole brain | 3, 6, 12, 24, 48, 72 h; 1, 2, 4 weeks | FKN overexpression promotes M2 phenotypic polarization, reverses the reduced neural stem cell in hippocampus, decreases the TNF-α level, and increases the IL-10 level in the blood. | [ |
| BV-2 | γ-ray with 10 Gy | 1.5, 6 h | FKN promotes microglial phagocytosis and M2 polarization, decreases TNF-α and IL-1β mRNA levels, and increases IL-10 mRNA levels. CX3CR1 knockdown reverses these effects. | [ | ||
| PPARα | BV-2 | γ-ray with 10 Gy | 1, 3, 7, 12, 24 h | PPARα activation prevents the increase in IL-1, and TNF-α mRNA levels, and COX-2 protein via inhibition of p65 translocation and jun phosphorylation. | [ | |
| 129S1/SvImJ mouse | γ-ray with 10 Gy | whole brain | 1 week, 2 months | PPARα activation promotes newborn neuron survival and prevents microglial activation. PPARα knockout abolishes the neuroprotection of fenofibrate. | [ | |
| Fischer 344 × Brown Norway rats | γ-ray with four fractions of 10 Gy | whole brain | 26, 29 weeks | PPARα activation prevents perirhinal cortex-dependent cognitive impairment without a decrease in microglial activation and an increase in immature neurons. | [ | |
| PPARδ | BV-2 | γ-ray with 10 Gy | 30 min; 7, 24 h | PPARδ activation downregulates ROS production, IL-1 and TNF-α expression, and COX-2 and MCP-1 proteins by inhibiting NF-κB and PKCα/MEK1/2/ERK1/2/AP pathways. | [ | |
| C57BL/6J | γ-ray with 10 Gy | whole brain | 3 h; 1, 2 weeks | PPARδ activation prevents the increase in IL-1 gene expression and pERK protein but does not rescue neurogenesis and hippocampal-dependent cognitive impairment. | [ | |
| PPARγ | Fischer 344 rat | γ-ray with nine fractions of 5 Gy (4.41 Gy/min) | whole brain | 50, 54 weeks | PPARγ activation prevents cognitive impairment. | [ |
| Kv 1.3 | Balb/c mouse | ß-ray with 30 Gy | whole brain | 3, 14 days; 8 weeks | Kv 1.3 blockade prevents neuronal loss and increases activated microglial in hippocampus and cerebral cortex and improves spatial learning and cerebral cortex atrophy in mice. | [ |
| BV-2 | ß-ray with 10 Gy | 4, 12 h; 1, 2 days | Kv 1.3 blockade or knockdown decreases protein and mRNA level of TNF-α, IL-6, and COX-2 in microglia and inhibits apoptosis of co-cultured primary hippocampal neurons. | [ | ||
| miR-124 | C57BL/6J mouse | γ-ray with 10 Gy | whole brain | 5 weeks | miR-124 overexpression prevents microglia activation and ameliorates cognitive impairment. | [ |
| miR-741-3p | C57BL/6J mouse | ß-ray with 30 Gy | whole brain | 1, 6 weeks | miR-741-3p inhibition resists cognitive dysfunction, hippocampal neuronal injury, and microglia activation and decreases the expression level of IL-6 and TNF-a. | [ |
| miR-122-5p | C57BL/6J mouse | ß-ray with 30 Gy | whole brain | 6 weeks, 48–50 days | miR-122-5p inhibition prevents cognitive impairment, neuronal damage, microglia activation, and production of TNF-a, IL-6, and IL-1ß in hippocampus. | [ |
| BV-2 | ß-ray with 10 Gy | 8, 24 h | miR-122-5p inhibition alleviates the decrease in cell viability and increase in the release of TNF-a, IL-6, and IL-1ß in BV2; restores BV2 branching morphogenesis and phagocytosis; and reduces co-cultured SH-SY5Y cell apoptosis. | [ | ||
| lncRNA ENSMUST00000130679 | BV-2 | X-ray with 10 Gy | 1, 24 h | lncRNA ENSMUST00000130679 knockdown suppresses DDR; phosphorylation of p65, JNK, and p38; and release of TNF-a, IL-6, and IL-1ß in BV2. | [ | |
| lncRNA ENSMUST00000190863 | BV-2 | X-ray with 10 Gy | 1, 24 h | lncRNA ENSMUST00000190863 knockdown suppresses DDR, phosphorylation of p65, and release of TNF-a in BV2. | [ | |
| hNSC-derived MV | athymic nude rats | X-ray with 10 Gy | whole brain | 4–7 weeks | MV transplantation into the bilateral hippocampus reduces the number of activated microglia in the hippocampus, neocortex (layer II/III), and amygdala; recovers the complexity of neuronal architecture; and ameliorates cognitive impairment. | [ |
| 1 month | MV transplantation into the unilateral hippocampus reduces the number of activated microglia in the ipsilateral hippocampus; bilateral or unilateral transplantation increases GDNF and restores PSD-95 protein level in bilateral hippocampus; neither bilateral nor unilateral transplantation protects dendritic spine density. | [ | ||||
| hNSC-derived EV | C57BL/6J mouse | γ-ray with 10 Gy | whole brain | 5 weeks, 6 months | EV transplantation into the bilateral hippocampus prevents microglia activation in the hippocampus and ameliorates cognitive impairment. | [ |
| ADMSC-Exos | Sprague–Dawley rats | γ-ray with 30 Gy | whole brain | 24 h; 3, 7 days | Tail vein injection pf ADMSC-Exos decreases the levels of caspase-3, MDA, 8-OHdG, TNF-α, IL-4, and SIRT1 and promotes recovery of SOD, CAT, IL-4, and IL-10 levels and suppresses microglial infiltration. | [ |
| primary microglia | γ-ray with 30 Gy | 24 h | Tail vein injection of ADMSC-Exos decreases the levels of caspase-3, MDA, 8-OHdG, TNF-α, IL-4, and SIRT1 and promotes the recovery of SOD, CAT, IL-4, and IL-10 levels and suppresses microglial activation. The above effects of ADMSC-Exos are inhibited by the SIRT-1 inhibitor EX527. | [ |